Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain
Officers.
On May 11, 2017, the Leadership Development and Compensation
Committee (the Committee) of the Board
of Directors of Amyris, Inc. (the
Company) approved bonus payments for
the Companys fiscal quarter ended March 31, 2017 to the Companys
executives, including the Companys current named executive
officers listed in the Companys definitive proxy statement filed
with the Securities and Exchange Commission (the
SEC)on April 27, 2017 (the
NEOs), under the Companys 2017 cash
bonus plan (the Bonus Plan), which
included an exercise of discretion by the Committee to award a
one-time cash bonus, in addition to the plan-based bonus, in the
amount of $300,000 to John Melo, the Companys president and chief
executive officer.
In addition, on May 11, 2017, the Committee approved 2017 target
bonuses for the NEOs under the Bonus Plan as follows:
|
Named Executive Officer |
Title |
Target Bonus (%ofBase Salary) |
|
| John Melo | President and Chief Executive Officer | 50% | |
| Kathleen Valiasek | Chief Financial Officer | 40% | |
| Joel Cherry | President, Research and Development | 50% |
Actual amounts paid to the NEOs under the Bonus Plan may be more
or less than the target bonus amounts in accordance with the
terms of the Bonus Plan, which were previously reported in a
Current Report on Form 8-K filed with the SEC on March 10, 2017,
which is incorporated herein by reference.
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product. Amyris, Inc. (NASDAQ:AMRS) Recent Trading Information
Amyris, Inc. (NASDAQ:AMRS) closed its last trading session down -0.030 at 0.260 with 7,815,971 shares trading hands.
